Comparative Performance Evaluation of Personal Protective Measures and Antiviral Agents Against SARS-CoV-2 Variants: A Narrative Review

Scientists identified SARS-CoV-2 in December 2019 in Wuhan city of China. Soon after its identification, Covid-19 spreads almost everywhere. The World Health Organization (WHO) declared the Covid-19 outbreak as a pandemic on March 11, 2020. Countries are facing multiple waves due to the different variants of the coronavirus. Personal preventive measures, vaccines, and antiviral drugs are the approaches to control Covid-19. However, these approaches are being implemented in different countries at different levels because of the availability of personal protective measures and antiviral agents. The objective of this study was to evaluate the effectiveness of practicing measures to fight the Covid-19 pandemic. Here we searched relevant literature from PubMed and Scopus using the keywords such as personal protective measures, antiviral agents, and vaccine effectiveness. According to the present findings, protective measures were found comparatively less effective. Nevertheless, these measures can be used to limit the spreading of Covid-19. Antiviral agents can reduce the hospitalization rate and are more effective than personal protective measures. The most effective strategy against Covid-19 is early vaccination or multiple vaccination dose. The respective authorities should ensure equal distribution of vaccines, free availability of antiviral drugs, and personal protective measure in poor and developing countries. We recommend more studies to describe the effectiveness of practicing preventive measures and antiviral agents against recent variants of the coronavirus.

[1]  Md. Rabiul Islam,et al.  Risk evaluation and mitigation strategies for newly detected SARS‐CoV‐2 Omicron BF.7 subvariant: A brief report , 2023, Health science reports.

[2]  Mohammad Fahim Kadir,et al.  The re-emergence of COVID-19 in China is a big threat for the world: Associated risk factors and preventive measures , 2023, Annals of medicine and surgery.

[3]  M. Bhuiyan,et al.  SARS‐COV‐2 Omicron subvariant BF.7 is again triggering the Covid fear: What we need to know and what we should do? , 2023, Journal of medical virology.

[4]  H. Harapan,et al.  Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies , 2022, Journal of Infection and Public Health.

[5]  Md. Rabiul Islam,et al.  Increasing reinfections and decreasing effectiveness of COVID-19 vaccines urge the need for vaccine customization , 2022, Annals of Medicine and Surgery.

[6]  M. Shahriar,et al.  The latest Omicron BA.4 and BA.5 lineages are frowning toward COVID‐19 preventive measures: A threat to global public health , 2022, Health science reports.

[7]  Chuanlong Zhu,et al.  The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial , 2022, Frontiers in Medicine.

[8]  Sheikh Mansoor,et al.  Inactivated vaccine Covaxin/BBV152: A systematic review , 2022, Frontiers in Immunology.

[9]  E. Zarenezhad,et al.  Paxlovid: Mechanism of Action, Synthesis, and In Silico Study , 2022, BioMed research international.

[10]  Sarah E. Wilson,et al.  Vaccine Effectiveness of BNT162b2 Against Delta and Omicron Variants in Adolescents. , 2022, Pediatrics.

[11]  Hongzhou Lu,et al.  Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial , 2022, Frontiers in Pharmacology.

[12]  M. Hasan,et al.  Comparative evaluation of authorized drugs for treating Covid‐19 patients , 2022, Health science reports.

[13]  M. Hernán,et al.  Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study , 2022, The Lancet Infectious Diseases.

[14]  Zhou Zhou,et al.  Role of COVID-19 Vaccines in SARS-CoV-2 Variants , 2022, Frontiers in Immunology.

[15]  S. Gharbia,et al.  Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.

[16]  A. Diacon,et al.  Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study , 2022, The Lancet.

[17]  G. Lippi,et al.  Highly efficient respirators are needed for the Omicron variant of SARS-CoV-2 , 2022, Public Health.

[18]  E. Giovannucci,et al.  Comparative effectiveness of N95, surgical or medical, and non‐medical facemasks in protection against respiratory virus infection: A systematic review and network meta‐analysis , 2022, Reviews in medical virology.

[19]  Yahiya Y. Syed.  Molnupiravir: First Approval , 2022, Drugs.

[20]  P. Austin,et al.  Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario , 2022, Nature Microbiology.

[21]  C. Chakraborty,et al.  Omicron (B.1.1.529) variant of SARS‐CoV‐2: Concerns, challenges, and recent updates , 2022, Journal of medical virology.

[22]  J. Roberts,et al.  Pandora’s box: Paxlovid, prescribing, pharmacists and pandemic , 2022, Journal of pharmacy practice and research : official journal of the Society of Hospital Pharmacists of Australia.

[23]  Chenyu Sun,et al.  It is not the time to relax yet: masks are still needed for the Omicron variant of SARS-CoV-2 , 2022, Public Health.

[24]  D. Khanna,et al.  A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson , 2022, Human vaccines & immunotherapeutics.

[25]  Sohel Daria,et al.  The SARS‐CoV‐2 omicron wave is indicating the end of the pandemic phase but the COVID‐19 will continue , 2022, Journal of medical virology.

[26]  M. Klompas,et al.  Preventing SARS-CoV-2 Transmission in Health Care Settings in the Context of the Omicron Variant. , 2022, JAMA.

[27]  Md. Jamal Hossain,et al.  The SARS‐CoV‐2 Omicron (B.1.1.529) variant and effectiveness of existing vaccines: What we know so far , 2022, Journal of medical virology.

[28]  Md. Jamal Hossain,et al.  Emerging SARS-CoV-2 Variants and Subvariants: Challenges and Opportunities in the Context of COVID-19 Pandemic , 2022, Environmental health insights.

[29]  Md. Rabiul Islam,et al.  New Coronavirus Variants are Creating More Challenges to Global Healthcare System: A Brief Report on the Current Knowledge , 2022, Clinical pathology.

[30]  Neeti Zaman Bintee,et al.  The Impact of Community Masking on COVID-19: A Cluster-Randomized Trial in Bangladesh , 2021 .

[31]  M. Landray,et al.  Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, medRxiv.

[32]  Haitao Zhu,et al.  The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6–14 years: a cohort study , 2021, Annals of translational medicine.

[33]  Naganathan Pillai,et al.  COVID-19 Vaccine: Review of the Mechanism of Action of Different Types of Vaccine , 2022, OALib.

[34]  J. Skarbinski,et al.  Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients , 2021, The New England journal of medicine.

[35]  M. Delpino,et al.  Omicron variant of the SARS-CoV-2: a quest to define the consequences of its high mutational load , 2021, GeroScience.

[36]  J. Lopez Bernal,et al.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Reply. , 2021, The New England journal of medicine.

[37]  Ikbel Hadj Hassine.  Covid‐19 vaccines and variants of concern: A review , 2021, Reviews in medical virology.

[38]  Elisabeth Mahase.  Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports , 2021, BMJ.

[39]  W. Blackwelder,et al.  Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial , 2021, The Lancet.

[40]  C. Fjell,et al.  Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada , 2021, medRxiv.

[41]  A. Sheikh,et al.  BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant , 2021, The New England journal of medicine.

[42]  Md. Rabiul Islam.  Urgent call for mass immunization against coronavirus in Bangladesh , 2021, Science progress.

[43]  Anoop Misra,et al.  Molnupiravir in COVID-19: A systematic review of literature , 2021, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[44]  M. Hernán,et al.  Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study , 2021, The Lancet.

[45]  K. Bruxvoort,et al.  Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study , 2021, BMJ.

[46]  Md. Rabiul Islam,et al.  The “Delta Plus” COVID-19 variant has evolved to become the next potential variant of concern: mutation history and measures of prevention , 2021, Journal of basic and clinical physiology and pharmacology.

[47]  Wildo Navegantes de Araújo,et al.  Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study , 2021, BMJ.

[48]  M. de Angelis,et al.  Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety , 2021, Infection and drug resistance.

[49]  A. Candevir,et al.  How efficient are facial masks against COVID-19? Evaluating the mask use of various communities one year into the pandemic , 2021, Turkish journal of medical sciences.

[50]  Gheyath K Nasrallah,et al.  mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar , 2021, Nature Medicine.

[51]  P. Kalra,et al.  Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine , 2021, The New England journal of medicine.

[52]  M. Hassany,et al.  Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. , 2021, JAMA.

[53]  J. Chan,et al.  Physical distancing implementation, ambient temperature and Covid-19 containment: An observational study in the United States , 2021, Science of The Total Environment.

[54]  L. Abu-Raddad,et al.  Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants , 2021, The New England journal of medicine.

[55]  Y. Zuo,et al.  Face masks against COVID-19: Standards, efficacy, testing and decontamination methods , 2021, Advances in Colloid and Interface Science.

[56]  H. Fennema,et al.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.

[57]  W. Dowling,et al.  Status Report on COVID-19 Vaccines Development , 2021, Current Infectious Disease Reports.

[58]  D. Bonsall,et al.  Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial , 2021, The Lancet.

[59]  V. Munster,et al.  Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques , 2021, Nature.

[60]  D. Lauffenburger,et al.  Publisher Correction: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques , 2021, Nature.

[61]  M. Hasan,et al.  The COVID-19 vaccination experience in Bangladesh: Findings from a cross-sectional study , 2021, International journal of immunopathology and pharmacology.

[62]  A. Boretti.  Efficacy of Generalized Face Masking Mandates , 2021, Health services research and managerial epidemiology.

[63]  W. Guan,et al.  Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case–control real-world study , 2021, Emerging microbes & infections.

[64]  S. Perna,et al.  A review on COVID-19 vaccines: stages of clinical trials, mode of actions and efficacy , 2021, Arab Journal of Basic and Applied Sciences.

[65]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[66]  Xiaoshuang Liu,et al.  Differential impact of non-pharmaceutical public health interventions on COVID-19 epidemics in the United States , 2020, BMC Public Health.

[67]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[68]  K. Dheda,et al.  KN95 filtering facepiece respirators distributed in South Africa fail safety testing protocols. , 2020, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[69]  Y. Gan,et al.  Relationship Between COVID-19 Infection and Risk Perception, Knowledge, Attitude, and Four Nonpharmaceutical Interventions During the Late Period of the COVID-19 Epidemic in China: Online Cross-Sectional Survey of 8158 Adults , 2020, Journal of medical Internet research.

[70]  David J Weber,et al.  Filtration Efficiency of Hospital Face Mask Alternatives Available for Use During the COVID-19 Pandemic. , 2020, JAMA internal medicine.

[71]  V. Munster,et al.  ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques , 2020, Nature.

[72]  Christoph Nitsche,et al.  The SARS-CoV-2 main protease as drug target , 2020, Bioorganic & Medicinal Chemistry Letters.

[73]  H. Tian,et al.  Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China , 2020, BMJ Global Health.

[74]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[75]  J. Samet,et al.  Food and Drug Administration , 2007, BMJ : British Medical Journal.

[76]  John Jackson,et al.  Futures? , 2000 .

[77]  C. Dolea,et al.  World Health Organization , 1949, International Organization.